James M. Hinson
Corporate Officer/Principal bei Unicorn Pharma Consulting, Inc.
Aktive Positionen von James M. Hinson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Unicorn Pharma Consulting, Inc. | Corporate Officer/Principal | 06.11.2009 | - |
Karriereverlauf von James M. Hinson
Ehemalige bekannte Positionen von James M. Hinson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Aldagen, Inc.
 Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Technik-/Wissenschafts-/F&E-Leiter | 06.11.2009 | - |
| Corporate Officer/Principal | 06.11.2009 | 06.11.2009 |
Ausbildung von James M. Hinson
| University of Missouri | Undergraduate Degree |
| Vanderbilt University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Health Technology |
| Unicorn Pharma Consulting, Inc. |
- Börse
- Insiders
- James M. Hinson
- Erfahrung
